FDA to review Medivation-Astellas prostate cancer drug in November
04:18 EDT 6 Aug 2012 | SmartBrief
The FDA is set to evaluate MDV3100, or enzalutamide, an investigational prostate cancer drug from Medivation and Astellas Pha -More-
Original Article: FDA to review Medivation-Astellas prostate cancer drug in November
More From BioPortfolio on "FDA to review Medivation-Astellas prostate cancer drug in November"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
